GENEVA, Switzerland (NBC) –A World Health Organization trial found the US company Gilead Science’s Remdesivier had no impact on survival rates of those infected with COVID-19.
After its findings, WHO said its “solidarity trial” will continue and it would assess monoclonal antibodies and other antiviral drugs in its trial of potential COVID-19 treatments.
WHO Chief Scientist Soumya Swaminathan said, “A number of countries, a number of developers are working on vaccines – we want to work with all of them, support them where we can, advise or guide about our own procedures. So we had a good tele-conference with the Russian developers of the second vaccine.”
Gilead responded, saying the trial’s findings appeared inconsistent with evidence from other studies.